Genomma Lab Internacional, S.A.B. de C.V.
LABB
Rank in Stocks
#9541
Genomma Lab Internacional, S.A.B. de C.V., along with its subsidiary companies,... Genomma Lab Internacional, S.A.B. de C.V., along with its subsidiary companies, specializes in the formulation, promotion, and worldwide distribution of non-prescription pharmaceuticals and personal hygiene products. The firm's extensive product range covers areas such as skincare, general health and wellness, haircare, pain management, cold and flu remedies, gastrointestinal treatments, sexual health, antiperspirant deodorants, hand sanitizers, rehydration drinks, and shaving essentials. It also provides analgesics, antifungal solutions, and hemorrhoid treatments. These items are sold under numerous recognized brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, TΓo Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Incorporated in 1996, Genomma Lab Internacional, S.A.B. de C.V. is headquartered in Mexico City, Mexico.
Share Price
$0.85021807
Last synced: 2026-11-09
Market Cap
$831.30M
Change (1 day)
-0.73%
Change (1 year)
-12.91%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Genomma Lab Internacional, S.A.B. de C.V. (LABB)
Category
Healthcare
Operating Margin for Genomma Lab Internacional, S.A.B. de C.V. (LABB)
Operating Margin as of November 2026 TTM: 19.91%
According to Genomma Lab Internacional, S.A.B. de C.V.'s latest financial reports, its current operating margin (TTM) is 19.91%. At the end of 2025 the company had an operating margin of 21.43%.
Operating Margin history for Genomma Lab Internacional, S.A.B. de C.V. from 2005 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 19.91% | -7.09% |
| 2025 | 21.43% | 1.66% |
| 2024 | 21.08% | 6.46% |
| 2023 | 19.80% | 2.64% |
| 2022 | 19.29% | -1.93% |
| 2021 | 19.67% | -1.45% |
| 2020 | 19.96% | 8.89% |
| 2019 | 18.33% | -6.05% |
| 2018 | 19.51% | -6.92% |
| 2017 | 20.96% | -242.29% |
| 2016 | -14.73% | 66.82% |
| 2015 | -8.83% | -141.67% |
| 2014 | 21.19% | -18.03% |
| 2013 | 25.85% | 1.65% |
| 2012 | 25.43% | -0.20% |
| 2011 | 25.48% | -1.16% |
| 2010 | 25.78% | 4.58% |
| 2009 | 24.65% | -14.05% |
| 2008 | 28.68% | 18.56% |
| 2007 | 24.19% | 29.50% |
| 2006 | 18.68% | -202.98% |
| 2005 | -18.14% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -99.03% |
DE
|
|
| 19.68% | -99.01% |
DE
|
|
| 13.26% | -99.33% |
JP
|
|
| 17.08% | -99.14% |
CH
|
|
| 14.92% | -99.25% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Genomma Lab Internacional, S.A.B. de C.V.'s operating margin
What is Genomma Lab Internacional, S.A.B. de C.V.'s operating margin?
Genomma Lab Internacional, S.A.B. de C.V.'s operating margin is 19.91%, as of Nov 2026.
What was Genomma Lab Internacional, S.A.B. de C.V.'s operating margin in 2025?
In 2025, Genomma Lab Internacional, S.A.B. de C.V.'s operating margin was 21.43%, compared with 21.08% in 2024.
How has Genomma Lab Internacional, S.A.B. de C.V.'s operating margin changed since 2020?
From 2020 to 2025, Genomma Lab Internacional, S.A.B. de C.V.'s operating margin was highest in 2025 (21.43%) and lowest in 2022 (19.29%).
How does Genomma Lab Internacional, S.A.B. de C.V.'s operating margin compare with similar companies?
Genomma Lab Internacional, S.A.B. de C.V.'s operating margin (19.91%) is higher than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.